Association of High Neutrophil-to-Lymphocyte Ratio With Poor Outcomes of Pembrolizumab Therapy in High-PD-L1-expressing Non-small Cell Lung Cancer

Tsukasa Hasegawa, Noriko Yanagitani, Hirofumi Utsumi, +13

Anticancer Research

Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with anti-programmed cell death-1/ligand 1 inhibitors

Takehiro Tozuka, Satoru Kitazono, Hiroaki Sakamoto, +12

BMC Cancer

Addition of ramucirumab enhances docetaxel efficacy in patients who had received anti-PD-1/PD-L1 treatment

Takehiro Tozuka, Satoru Kitazono, Hiroaki Sakamoto, +12

Lung Cancer

Translational MedicineImmunologyPharmacologyAnti-pd-1/pd-l1 TreatmentTherapeutic Efficacy +5

Pembrolizumab-induced agranulocytosis in a pulmonary pleomorphic carcinoma patient who developed interstitial lung disease and ocular myasthenia gravis

Takehiro Tozuka, Teppei Sugano, Rintaro Noro, +12

Oxford Medical Case Reports

VasculitisAutoimmune DiseaseGranulocyteMedicineImmunology +13

Feasibility of next‐generation sequencing test for patients with advanced <scp>NSCLC</scp> in clinical practice

Ryo Ariyasu, Ken Uchibori, Hironori Ninomiya, +11

Thoracic Cancer

Impact of Renin–angiotensin System Inhibitors on the Efficacy of Anti-PD-1/PD-L1 Antibodies in NSCLC Patients

Takehiro Tozuka, Noriko Yanagitani, Hiroshi Yoshida, +11

Anticancer Research

Poor efficacy of anti‐programmed cell death‐1/ligand 1 monotherapy for non‐small cell lung cancer patients with active brain metastases

Takehiro Tozuka, Satoru Kitazono, Hiroaki Sakamoto, +12

Thoracic Cancer

Osimertinib plus local treatment for brain metastases versus osimertinib alone in patients with EGFR-Mutant Non-Small Cell Lung Cancer

Takehiro Tozuka, Rintaro Noro, Hideaki Mizutani, +14

Lung Cancer

Brain MetastasesMedicinePathologyLocal TreatmentBronchial Neoplasm +4

Association Between the Efficacy of Pembrolizumab and Low STK11/LKB1 Expression in High-PD-L1-expressing Non-small-cell Lung Cancer

Tsukasa Hasegawa, Noriko Yanagitani, Hironori Ninomiya, +11

In Vivo

Second-line immunosuppressant administration for steroid-refractory immune-related adverse events in patients with lung cancer

Shinsuke Ogusu, Yuhei Harutani, Takehiro Tozuka, +10

Cancer Immunology Immunotherapy